NCT05380323

A Study of LY3541105 in Healthy and Overweight Participants

A Phase 1, Randomized, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, and PK of LY3541105 Following Single Doses in Healthy/Overweight Participants and Multiple Doses in Overweight Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 206 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 21 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The main purpose of this study is to evaluate the safety and tolerability of LY3541105 in healthy and overweight participants. Blood tests will be performed to check how much LY3541105 gets into the bloodstream and how long it takes the body to eliminate it. The study will also evaluate the effects of LY3541105 on body weight and assess safety and tolerability of LY3541105. This is a 3-part study and may last up to 15, 26 and 24 weeks for each participant and may include up to 7, 15 and 16 visits in parts A, B and C, respectively.

Conditions

• Overweight
• Healthy

Interventions

Type	Name	Description
DRUG	LY3541105	Administered SC.
DRUG	Placebo	Administered SC.

Timeline

• Start date: 2022-05-10
• Primary completion: 2024-08-27
• Completion: 2024-08-27
• First posted: 2022-05-18
• Last updated: 2025-06-27

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study